clinical and functional consequences associated to a pkp2 founder
TRANSCRIPT
![Page 1: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/1.jpg)
Session: Advances in genetics of cardiomyopathies
Clinical and functional consequences
associated to a PKP2 founder mutation in
north-west Spain
Presenter: Lorenzo Monserrat
Paris, 28 Aug 2011
A. Diez-Juan , MF. Ortiz, L. Perez-Alvarez, R. Barriales-Villa, DA. Garcia, J.
Moncayo-Arlandi, X. Fernandez, L. Nunez, L. Monserrat
![Page 2: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/2.jpg)
Potential conflicts of interest
Lorenzo Monserrat:
Promoter and Stockholder:
Health in Code
![Page 3: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/3.jpg)
•Primary and inherited affection of the myocardium(estimated
prevalence 1:5000 )
•Progressive replacement of right ventricular myocardium with
adipose and fibrous tissue (mainly RV, but also LV)
ARVC
![Page 4: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/4.jpg)
DESMOSOMAL GENES
www.e-heart.org
![Page 5: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/5.jpg)
•25 unrelated index cases with ARVC from A Coruña
(Galicia-Spain)
•Sequence analysis of 4 main desmosomal genes:
•Plakophilin-2 (PKP2)
•Desmoplakin (DSP)
•Desmoglein-2 (DSG2)
•Desmocollin-2 (DSC2)
COHORT
![Page 6: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/6.jpg)
GEOGRAPHICAL DISTRIBUTION
![Page 7: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/7.jpg)
•10 mutations (9 novel) in 17 of 25 pts 68%
•4 pts complex genotypes 16%
•1 homozygous
•1 compound heterozygous
•2 doble heterozygous
•3 mutations in more than 1 proband
•S329RfsX351 in PKP2 (9 cases)
•R375X in DSC2 (2 cases)
•C813R in DSG2 (2 cases)
GENETIC STUDIES
![Page 8: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/8.jpg)
PROBAND PKP2 DSP DSC2 DSG2
1 S329RfsX351
2 S329RfsX351
3* S329RfsX351
E624D
4* S329RfsX351 K468Q
5 S329RfsX351
6* S329RfsX351 R375X
7 S329RfsX351
8 S329RfsX351
9 S329RfsX351
10* R375X (H)
11 IVS11+2T>C
12 M589T
13 IVS9-1G>C
14 R1945C
15 R907L
16 C813R
17 C813R
* Complex genotypes
![Page 9: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/9.jpg)
18 carriers
8 non carriers
49 without
genetic study
9 families
S329RfsX351 – PKP2
8 ARVC
7 possible ARVC
3 not affected or healthy
1 possible ARVC
7 not affected or healthy
1 ARVC
1 possible ARVC
3 not affected or healthy,
44 without phenotypic study
![Page 10: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/10.jpg)
Events in mutation carriers
2 Sudden deaths
4 Appropiate ICD shocks
1 Stroke related death
2 Strokes without death
Events in relatives without genetic study
3 Sudden deaths
2 Stroke related deaths
1 Stroke without death
EVENTS
![Page 11: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/11.jpg)
SD
SD SD
aSD
aSD
ICDs
ICDs
ICDs
ICDs
HCM HCM
Stroke Stroke
x2
Stroke
Stroke
Stroke
![Page 12: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/12.jpg)
Table - Genetic and clinical characteristics of S329RfsX351-PKP2 carriers
![Page 13: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/13.jpg)
![Page 14: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/14.jpg)
Table - Clinical characteristics of relatives without genetic diagnosis who had
adverse events
![Page 15: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/15.jpg)
Fressart et al. Europace 2010;12:861-868
300
healthy
controls
![Page 16: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/16.jpg)
?
![Page 17: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/17.jpg)
PKP2 –
S329RfsX351
•Costa da Morte
(Death coast)
FOUNDER
EFFECT
![Page 18: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/18.jpg)
PKP 2: Constructions
S329fsX351
(pb4086)
Armadillo domain Variable domain
N
´ C
´
hPKP2 V5
Esmeral V5 mPKP2
Esmeral V5 mPKP2
(Control)
Esmeral V5
Experimentals
S329fsX351
EXT
INT
INT
Plakophilin 2
S329fsX351
Control
![Page 19: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/19.jpg)
H9C2
Rat ventricular cardiomyocytes
HL-1
Mouse atrial cardiomyocytes
Neonatal Cardiomyocytes
Rat ventricular cardiomyocytes
Esmeral V5
mPKP2
Esmeral V5 mPKP2
Esmeral V5
hPKP2 V5
S329fsX351
Esmeral V5 mPKP2
S329fsX351
Lentiviral vector
![Page 20: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/20.jpg)
hPKP2
-v5
hPKP2
-v5 Control Control
Cytoplasmic Nuclear
v5
hPKP2
-v5
hPKP2
-v5 Control Control
Cytoplasmic Nuclear
PKP2
hPKP2 V5 mPKP2
Control Control hPKP2-v5 hPKP2-v5
HL-1
Mouse Atrial Cardiomiocytes
α- Tubulin α- Tubulin
Anti V5 Anti C-term
![Page 21: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/21.jpg)
HL-1
Mouse Atrial Cardiomiocytes
Control hPKP2-v5 Control hPKP2-v5
γ-catenin Desmoplakin
![Page 22: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/22.jpg)
Neonatal rat
ventricular
cardiomyocytes
Control hPKP2-v5
Anti-v5
Anti-PKP2
↑↑ PPAR-γ (Adipogenic factor)
↑ TGF-β2 and TGF β3 (Fibrosis factors)
↑ Vimentin (Adipogenic marker)
Fibrosis
factors
Adigogenic
marker
hPKP2 V5
![Page 23: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/23.jpg)
CONCLUSIONS
•Mutations in 70% of ARVC cases
•S329RfsX351-PKP2 is a pathogenic mutation
associated with the development of ARVC
•Founder mutation in Galicia
•Incomplete penetrance in young carriers
•Severe expression in cases with additional
pathogenic mutations
•Arrhythmic sudden death and strokes
•LV involvement relatively common
![Page 24: Clinical and functional consequences associated to a PKP2 founder](https://reader031.vdocuments.us/reader031/viewer/2022021211/620654ba8c2f7b173006be01/html5/thumbnails/24.jpg)
CONCLUSIONS
•Functional studies:
•PKP2 not only a structural protein
•Nuclear localization of mutant PKP2 could
be responsible of anomalous cardiomyocyte
gene expression
•Support for a role for immunofluorescence
studies in the diagnosis of ARVC (Asimaki et al)